| Persistent use of evidence-based pharmacotherapy in heart failure is associated with improved outcomes. | |
| | |
MedLine Citation:
|
PMID: 17646585 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Undertreatment with recommended pharmacotherapy is a common problem in heart failure and may influence prognosis. We studied initiation and persistence of evidence-based pharmacotherapy in 107,092 patients discharged after first hospitalization for heart failure in Denmark from 1995 to 2004. METHODS AND RESULTS: Prescriptions of dispensed medication and mortality were identified by an individual-level linkage of nationwide registers. Inclusion was irrespective of left ventricular function. Treatment with renin-angiotensin inhibitors (eg, angiotensin-converting enzyme inhibitors and angiotensin-2 receptor blockers), beta-blockers, spironolactone, and statins was initiated in 43%, 27%, 19%, and 19% of patients, respectively. Patients who did not initiate treatment within 90 days of discharge had a low probability of later treatment initiation. Treatment dosages were in general only 50% of target dosages and were not increased during long-term treatment. Short breaks in therapy were common, but most patients reinitiated treatment. Five years after initiation of treatment, 79% patients were still on renin-angiotensin inhibitors, 65% on beta-blockers, 56% on spironolactone, and 83% on statins. Notably, multiple drug treatment and increased severity of heart failure was associated with persistence of treatment. Nonpersistence with renin-angiotensin inhibitors, beta-blockers, and statins was associated with increased mortality with hazard ratios for death of 1.37 (95% CI, 1.31 to 1.42), 1.25 (95% CI, 1.19 to 1.32), 1.88 (95% CI, 1.67 to 2.12), respectively. CONCLUSIONS: Persistence of treatment was high once medication was started, but treatment dosages were below recommended dosages. Increased severity of heart failure or increased number of concomitant medications did not worsen persistence, but nonpersistence identified a high-risk population of patients who required special attention. A focused effort on early treatment initiation, appropriate dosages, and persistence with the regimen is likely to provide long-term benefit. |
| | |
Authors:
|
Gunnar H Gislason; Jeppe N Rasmussen; Steen Z Abildstrom; Tina Ken Schramm; Morten Lock Hansen; Pernille Buch; Rikke Sørensen; Fredrik Folke; Niels Gadsbøll; Søren Rasmussen; Lars Køber; Mette Madsen; Christian Torp-Pedersen |
Related Documents
:
|
22765225 - Adherence to antiretroviral therapy in hiv-positive adolescents in uganda assessed by m... 11398915 - Perindopril: an updated review of its use in hypertension. 6753905 - Short and long-term effects of treatment with low dose captopril in patients with sever... 2944675 - Sequential echocardiographic study prior and during antihypertensive therapy in childre... 3197915 - Clinical evaluation of rectally administered ampicillin in acute otitis media. 22765225 - Adherence to antiretroviral therapy in hiv-positive adolescents in uganda assessed by m... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2007-07-23 |
Journal Detail:
|
Title: Circulation Volume: 116 ISSN: 1524-4539 ISO Abbreviation: Circulation Publication Date: 2007 Aug |
Date Detail:
|
Created Date: 2007-08-16 Completed Date: 2007-09-14 Revised Date: 2008-11-21 |
Medline Journal Info:
|
Nlm Unique ID: 0147763 Medline TA: Circulation Country: United States |
Other Details:
|
Languages: eng Pagination: 737-44 Citation Subset: AIM; IM |
Affiliation:
|
Department of Cardiology, Gentofte University Hospital, Hellerup, Denmark. gg@heart.dk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenergic beta-Antagonists
/
administration & dosage,
therapeutic use Adult Angiotensin-Converting Enzyme Inhibitors / administration & dosage, therapeutic use Cardiac Output, Low / drug therapy*, mortality Denmark Drug Prescriptions / statistics & numerical data Evidence-Based Medicine Hospital Mortality Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage, therapeutic use Patient Compliance Receptor, Angiotensin, Type 2 / antagonists & inhibitors Spironolactone / administration & dosage, therapeutic use Time Factors Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Adrenergic beta-Antagonists; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Receptor, Angiotensin, Type 2; 52-01-7/Spironolactone |
| Comments/Corrections | |
Comment In:
|
Circulation. 2007 Aug 14;116(7):693-5
[PMID:
17698742
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Stromal cell derived factor-1 alpha confers protection against myocardial ischemia/reperfusion injur...
Next Document: A decade of short-term outcomes in post cardiac surgery ventricular assist device implantation: data...